Kaléo, a pharmaceutical company has announced to offer a generic version of Evzio, the opioid antidote for $178 a carton, which will consist of auto-injector pens eligible for two single doses.
In April 2014, the US Food and Drug Administration approved Evzio after a prompt review obtained for the treatment of overdose of opioid, which is identified by a set of symptoms that are depleted breathing, decrease in heart rate, loss of consciousness, and others. In such cases, this drug was capable to get a proper control.
Naloxone is an active ingredient and is offered in an auto-injector pen that can be inserted into any muscle. It is easy-to-use and can be used by the patients or a family member regardless of a medical training. However, Evzio is not similar to Naloxone as the latter offers verbal instructions to the users.
In July 2014, the cost of the drug with the potential to save the lives was fixed at $575 but touched $4,100 in January 2017. Rob Portman, the Senator for Ohio mentioned that an investigation was carried out by the Permanent Subcommittee on Investigations that has proven that Kaléo has exploited the crisis of opioid by multiplying the price of naloxone drug Evzio by over 600% by the end of 2016. The investigation was carried out under the supervision of Committee on Homeland Security and Governmental Affairs, which stated that the elevated cost led to the capitalization of a fresh distribution model on the overdose of opioid at the epidemic level. Rob Portman is hopeful that the latest step will mobilize the access to naloxone, which is an important drug for the reversal of the effects of drug overdose, responsible for saving thousands of lives. The new generic of Evzio will be given at $178 for a two-dose pack, by mid-2019 through the subsidiary, IJ Therapeutics.